Dr Katie Lacy

Sub-specialties: Skin Cancer, Moles, Pigmented skin lesions, Benign and cancerous skin lesions, Melanoma, Skin cancer genetics, Acne, Rosacea, Skin Rashes, Eczema, Psoriasis.

Overview

02036532007

Overview

Dr Katie Lacy is experienced in treating patients with general dermatological conditions including eczema, psoriasis, acne, skin rashes and cancerous and benign skin lesion. Dr Lacy also has extensive experience of the use of mole mapping and dermoscopy in order to identify suspect skin lesions that require removal.

About Dr Katie Lacy

Dr Katie Lacy is a Consultant Dermatologist specialising in skin cancer, melanoma, moles, skin imaging with mole mapping and skin cancer genetics. She also sees patients over 18 for all general dermatological skin conditions. ,She trained in medicine at Pembroke College Oxford (where she was awarded a first-class degree in Natural Sciences) and the Royal Free Hospital. She trained as a Dermatologist in Bristol and has been a GMC-certified Dermatologist since 2008.

She was a Consultant Dermatologist at the St Johns Institute of Dermatology at Guys and St. Thomas’ Hospital for 12 years, where she was the Melanoma clinic lead and then subsequently overall clinical lead for skin cancer and the chair for the skin cancer South East London Cancer Alliance. In addition to Dermatology clinics, she also undertook a regional skin cancer genetics clinic at Guy's Hospital. Whilst at the St John’s Institute of Dermatology, she set up a specialist clinic for patients at high risk for the development of melanoma with multiple moles and the dysplastic naevus syndrome. She now works at Welbeck Skin Health and Allergy, where she continues to work with patients with multiple moles using the advanced Canfield VECTRA 3D mole mapping imaging system.

Whilst undertaking her Dermatology training, she also undertook a PhD in skin immunology at University College, London. She has remained active in research throughout her clinical career and was awarded a Reader position at King's College London whilst running research projects investigating melanoma immunology, on which she has published in prestigious peer-reviewed journals. She has presented her work at national and international meetings.

Areas of Expertise

Dr Katie Lacy performs a range of treatments including:

Some of the conditions she commonly treats are:

Additional Information

Qualifications

MA Physiological Sciences 1st Class Honours, Oxford University 1994
MBBS, London 1997
PhD, University College London 2008
Completion specialist training in Dermatology 2008
FRCP 2012

Awards

Roger Bannister Prize for Medicine, Pembroke College (Awarded for highest marks in finals) 1994
Hugh Wallace Registrar Presentation prize, Royal Society of Medicine 2008
St John’s Dermatological Society Medal for presentation on Melanoma and Pregnancy 2019

Memberships

British Association of Dermatologists
Royal College of Physicians
Royal Society of Medicine
British Medical Association
British Society for Investigative Dermatology
British Society of Immunology
International Dermoscopy Society

Research Highlights

Dr Katie Lacy has authored several peer-reviewed journals including:

Key Publications

Subramanian P, Sayegh S, Laphanuwat P, Devine OP, Fantecelle CH, Sikora J, Chambers ES, Karagiannis SN, Gomes DCO, Kulkarni A, Rustin MHA, Lacy KE, Akbar AN. Multiple outcomes of the germline p16^INK4a mutation affecting senescence and immunity in human skin. Aging Cell. 2025 Feb;24(2):e14373. Epub 2024 Oct 17.
Willsmore ZN, Booth L, Patel A, Di Meo A, Prassas I, Chauhan J, Wu Y, Fitzpartick A, Stoker K, Kapiris M, Biswas D, Perucha E, Whittaker S, Tsoka S, Diamandis EP, Middleton GW, Tull TJ, Papa S, Lacy KE, Karagiannis SN. Circulating immunoregulatory B cell and autoreactive antibody profiles predict lack of toxicity to anti-PD-1 checkpoint inhibitor treatment in advanced melanoma. J Immunother Cancer. 2025 May 31;13(5):e011682
Egbuniwe IU, Harris RJ, Nakamura M, Nestle FO, Akbar AN, Karagiannis SN, Lacy KE B Lymphocytes Accumulate and Proliferate in Human Skin at Sites of Cutaneous Antigen Challenge J Invest Dermatol. 2022 Mar; 142(3Part A): 726–731.e4. doi: 10.1016/j.jid.2021.06.038
Karagiannis P, Correa I, Chauhan J, Cheung A, Dominguez-Rodriguez D, Terranova-Barberio M, Harris RJ, Crescioli S, Spicer J, Bokemeyer C, Lacy KE, Karagiannis SN. Innate stimulation of B cells ex vivo enhances antibody secretion and identifies tumour-reactive antibodies from cancer patients. Clin Exp Immunol. 2022 Jan; 207(1): 84–94. Published online 2021 Dec 5. doi: 10.1093/cei/uxab005P
Adams R, Moser B, Karagiannis SN, Lacy KE. Chemokine Pathways in Cutaneous Melanoma: Their Modulation by Cancer and Exploitation by the Clinician. Cancers (Basel) 2021 Nov; 13(22): 5625. Published online 2021 Nov 10. doi: 10.3390/cancers13225625

Major insurers served

If your insurer is not listed, please contact us to confirm your coverage. Please note this does not guarantee coverage or fee assurance. Patients should confirm with their insurer to ensure coverage, check if the doctor is fee-assured, or verify if their policy includes the doctor in question.